Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | SQLE | Q14534 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2833684 | 0.92 | LMNA (0.39) | NR1I2LMNAPGRALDH1A1 | |
| SCHEMBL2833656 | 0.91 | NR1I2 (0.66) | NR1I2LMNAPGRALDH1A1FNTA | |
| SCHEMBL2838626 | 0.89 | NR1I2 (0.62) | NR1I2LMNAPGRALDH1A1FNTA | |
| SCHEMBL2835821 | 0.89 | NR1I2 (0.62) | NR1I2LMNAPGRALDH1A1FNTA | |
| SCHEMBL2832404 | 0.89 | NR1I2 (0.62) | NR1I2LMNAPGRALDH1A1FNTA | |
| SCHEMBL38776 | 0.88 | NR1I2 (0.58) | NR1I2LMNAPGRALDH1A1FNTA | |
| SCHEMBL2837988 | 0.88 | NR1I2 (0.58) | NR1I2LMNAPGRALDH1A1FNTA | |
| SCHEMBL2832502 | 0.87 | NR1I2 (0.54) | NR1I2LMNAPGRALDH1A1FNTA | |
| SCHEMBL2832988 | 0.85 | LMNA (0.55) | NR1I2LMNAPGRALDH1A1FNTA | |
| SCHEMBL2837914 | 0.85 | LMNA (0.55) | NR1I2LMNAPGRALDH1A1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866323-B1 | GLUCURONIDATED NEBIVOLOL | MYLAN LAB INC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-1848424-B1 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYLATED NEBIVOLOL | MYLAN LAB INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2808015-A1 | Compositions comprising nebivolol | MYLAN LABORATORIES, INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20110065783-A1 | HYDROXYLATED NEBIVOLOL METABOLITES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-17 | — | — | US | disclosed |
| US-7838552-B2 | Compositions comprising nebivolol | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-23 | — | — | US | disclosed |
| US-7763649-B2 | Carotenoid analogs or derivatives for controlling connexin 43 expression | CARDAX PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7723327-B2 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2174658-A1 | Compositions comprising nebivolol | MYLAN LABORATORIES, INC (US) | 2010-04-14 | — | — | EP | disclosed |
| US-7521584-B2 | Carotenoid analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1982711-A1 | Compositions comprsing nebivolol | MYLAN LABORATORIES, INC (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20050065097-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | CARDAX PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20050059635-A1 | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels | CARDAX PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| US-20050059659-A1 | Carotenoid analogs or derivatives for controlling C-reactive protein levels | CARDAX PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| US-20050049248-A1 | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels | CARDAX PHARMACEUTICALS, INC. | 2005-03-03 | — | — | US | disclosed |
| US-20050037995-A1 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | CARDAX PHARMA, INC. | 2005-02-17 | — | — | US | disclosed |
| US-20050026874-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| US-20050009930-A1 | Carotenoid analogs or derivatives for controlling connexin 43 expression | CARDAX PHARMA, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050009788-A1 | Carotenoid ester analogs or derivatives for controlling connexin 43 expression | CARDAX PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050009758-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMA, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050004235-A1 | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037995-A1 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | CPT1A, TXNRD2, PC | NR1I2 327/4885LMNA 1111/4885PGR 3696/4885 |
| US-20050009788-A1 | Carotenoid ester analogs or derivatives for controlling connexin 43 expression | GJA1, GJB2, CRY1 | NR1I2 1749/4885LMNA 29/4885PGR 2684/4885 |
| US-20050009930-A1 | Carotenoid analogs or derivatives for controlling connexin 43 expression | GJA1, GJB2, CRY1 | NR1I2 1843/4885LMNA 34/4885PGR 2818/4885 |
| US-20050059635-A1 | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels | TTPA, PROC, RBP4 | NR1I2 1487/4885LMNA 3024/4885PGR 2454/4885 |
| US-20050059659-A1 | Carotenoid analogs or derivatives for controlling C-reactive protein levels | RBP1, PROC, RBP4 | NR1I2 1858/4885LMNA 2708/4885PGR 2689/4885 |
| US-20050026874-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease | GYS2, HCCS, CPT1A | NR1I2 124/4885LMNA 716/4885PGR 2761/4885 |
| US-20050049248-A1 | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels | PROC, TTPA, CYC1 | NR1I2 1344/4885LMNA 2351/4885PGR 1989/4885 |
| US-20050065097-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | TXNRD2, GPX4, PC | NR1I2 263/4885LMNA 868/4885PGR 3443/4885 |
| US-20110065783-A1 | HYDROXYLATED NEBIVOLOL METABOLITES | EDNRB, EDNRA, ADRB1 | NR1I2 967/4885LMNA 862/4885PGR 4054/4885 |
| US-20050009758-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | NFE2L2, GPX4, CYP11B2 | NR1I2 645/4885LMNA 685/4885PGR 2215/4885 |
| US-20050004235-A1 | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease | GYS2, HCCS, CPT1A | NR1I2 164/4885LMNA 870/4885PGR 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.